You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

CORRECTION article

Front. Pharmacol., 02 December 2024

Sec. Experimental Pharmacology and Drug Discovery

Volume 15 - 2024 | https://doi.org/10.3389/fphar.2024.1515349

Corrigendum: Estrogens modulate somatostatin receptors expression and synergize with the somatostatin analog pasireotide in prostate cells

  • 1. Dipartimento di Medicina di Precisione, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy

  • 2. Dipartimento di Scienze Mediche, Chirurgiche, Neurologiche, Metaboliche e dell’Invecchiamento, Università degli Studi della Campania “Luigi Vanvitelli”, Naples, Italy

Article metrics

View details

712

Views

307

Downloads

In the published article, there was an error in Figure 5 as published. Figure 5C contained two different pictures representing different fields captured from the PPT-treated cells which had been assembled as two different conditions (PPT and E2+pas, respectively). Figure 5C should only contain an image captured from cells treated with E2+pas. The corrected Figure 5 and its caption appear below.

FIGURE 5

FIGURE 5

Effect of estradiol and pasireotide on EMT, morphology and motility of EPN cells. Quiescent EPN cells were untreated or treated for 48 h with the indicated compounds. Estradiol was used at 20 nM, pasireotide at 0.1 mM, PPT and DPN both at 3 nM. In panel (A), lysate proteins (2 mg/mL) were prepared, separated by SDS-PAGE and transferred to nitrocellulose membrane. Filters were immune-blotted using the antibodies against the indicated proteins. The blots are representative of two different experiments. In panel (B), the cells were analyzed for morphological changes using contrast-phase microscopy. Bar, 10 mM. In panel (C), the cells were wounded and then left unstimulated or stimulated with the indicated compounds. Cytosine arabinoside (20 mM) was added to the cell medium to avoid cell proliferation. Contrast-phase images in panel (B, C) are representative of 3 different experiments.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

prostate cancer, estrogens, somatostatin analogs, somatostatin receptors, apoptosis, EMT, migration

Citation

Rossi V, Di Zazzo E, Galasso G, De Rosa C, Abbondanza C, Sinisi AA, Altucci L, Migliaccio A and Castoria G (2024) Corrigendum: Estrogens modulate somatostatin receptors expression and synergize with the somatostatin analog pasireotide in prostate cells. Front. Pharmacol. 15:1515349. doi: 10.3389/fphar.2024.1515349

Received

22 October 2024

Accepted

21 November 2024

Published

02 December 2024

Volume

15 - 2024

Edited and reviewed by

Sergio Valente, Sapienza University of Rome, Italy

Updates

Copyright

*Correspondence: Gabriella Castoria,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics